Leerink Swann reaffirmed their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research note released on Saturday. Leerink Swann currently has a $66.00 price objective on the biotechnology company’s stock.

Several other analysts also recently commented on SRPT. ValuEngine upgraded Sarepta Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $76.00 target price on Sarepta Therapeutics and gave the company a buy rating in a research note on Thursday, June 8th. Royal Bank Of Canada reiterated a buy rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. BidaskClub upgraded Sarepta Therapeutics from a hold rating to a buy rating in a research note on Friday, June 23rd. Finally, Morgan Stanley reiterated an equal weight rating and set a $31.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Ten investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Sarepta Therapeutics has a consensus rating of Buy and a consensus target price of $62.71.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down 3.80% during mid-day trading on Friday, reaching $45.36. The company had a trading volume of 9,172,855 shares. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $63.73. The company has a 50 day moving average price of $40.10 and a 200 day moving average price of $34.92. The company’s market capitalization is $2.92 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the prior year, the business posted ($1.19) earnings per share. The business’s revenue for the quarter was up 350000.0% on a year-over-year basis. On average, analysts anticipate that Sarepta Therapeutics will post ($1.22) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Given Outperform Rating at Leerink Swann” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-given-outperform-rating-at-leerink-swann/1601074.html.

In other news, CFO Sandesh Mahatme sold 50,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Douglas S. Ingram acquired 47,058 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 78,056 shares of company stock valued at $3,224,208. Company insiders own 9.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. grew its position in shares of Sarepta Therapeutics by 1.4% during the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 129 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Advisor Group Inc. grew its position in shares of Sarepta Therapeutics by 3.2% during the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 326 shares in the last quarter. Legal & General Group Plc grew its position in shares of Sarepta Therapeutics by 3.9% during the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 663 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in shares of Sarepta Therapeutics by 0.8% during the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock valued at $3,703,000 after purchasing an additional 818 shares in the last quarter. Hedge funds and other institutional investors own 65.41% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.